| ON DC Oct.12, 2008 - Sahajanand Medical | | | | Revascularization) at (1%) Stent Thrombosis (2%) |
| Technologies Pvt. Ltd. (SMT), Surat, India, leading | | | | at 1 year and low angiographic in-segment |
| developer and manufacturer of drug-eluting | | | | restenosis rates (4.6%) at 8 months. The results |
| Stents, welcomed the positive results achieved by | | | | compare favorably to other drug eluting Stents |
| Supralimus Core (Sirolimus Eluting Stents on | | | | current in clinically practice. |
| unique chromium cobalt platform with a | | | | The 12 month results of MAXIMUS, which were |
| biodegradable Polymer) in the MAXIMUS trial. | | | | unveiled by Dr. Ashok Seth (Chairman and Chief |
| MAXIMUS trial was designed to assess the safety | | | | cardiologist, Escorts Heart Institute, New Delhi, |
| and efficacy of the Supralimus-Core (Sirolimus | | | | India) on Monday, October 12th at the |
| Eluting Stent) in de novo native obstructive | | | | Transcatheter Cardiovascular Therapeutics (TCT) |
| coronary artery disease. It included 100 patients | | | | conference in Washington, DC. |
| from the prestigious Max Heart institute in India. | | | | The results of Supralimus Core in a real world |
| The study population was reflective of real | | | | population with high incidence of diabetes and |
| world patients with smaller vessels, high | | | | relatively smaller vessels are extremely promising. |
| incidence of diabetes (36%) and other | | | | It also has the additional advantage of |
| cardiovascular risk factors. | | | | biodegradable polymer which disappears over a |
| The 8-months angiographic results, analyzed by | | | | period of time then alleviating some of the |
| Cardialysis (Rotterdam, Netherlands) showed | | | | concern related to persistent polymer |
| extremely low TLR (Target Lesion | | | | hypersensitivity. Dr Seth commented. |